Year-3 adherence and persistence research abstract Learn more about the methodology of Primes research study, GLP-1 Therapy to Treat Obesity Among Members Without Diabetes: Three-Year Persistence and Year-Over-Year Persistence Rate Change. Historical Adherence and persistence data Primes real-world, integrated data revealed further insights at Year 2, including that just 1 in 7 people remain on GLP-1 drugs for weight loss
Refill reminders make sure that medication stays consistent, avoiding gaps that could disrupt progress or cause withdrawal symptoms
Structure of the adenosine A2A receptor bound to an engineered G protein
These agonists can also stimulate receptors on vagal nerve cells in the stomach with the result that the stomach empties more slowly leading to a feeling of fullness
We therefore propose that GLP-1RAs exert chondroprotective effects in RA, at least in part, by suppressing ferroptosis in chondrocytes mediated by cGASSTING pathway
Why it matters: Inadequate protein accelerates muscle loss, slows metabolism, and undermines the long-term success of your weight loss